Interview: Steve Bates – CEO, BioIndustry Association (BIA), UK
Steve Bates, CEO of the UK BioIndustry Association (BIA) for over five years, shares the importance of the UK’s status as a global life science hub, the long-term government actions…
Address: 7th Floor, Southside
105 Victoria Street
London
SW1E 6QT
UK
Tel: +44 (0)20 7630 2180
Web: http://www.bioindustry.org/home/
The UK BioIndustry Association, the BIA, is the trade association for innovative enterprises involved in UK bioscience. Members include start-up, emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector.
The BIA works to further the interests of members and the industry – nationally and internationally. Our heritage of innovation, enterprise and success dates back to our founding over 20 years ago.
Influencing Progress
Bioscience is a national priority for the UK. The BIA works to encourage and promote a financially sound and thriving bioscience sector within the UK economy.
Our goal is to secure the UK’s position as a global hub and as the best location for innovative research and commercialisation, to help enable our world-leading research base to deliver healthcare solutions that can truly make a difference to people’s lives.
Lobbying is a core BIA strength. We provide a strong, unified, relentless voice for bioscience to stakeholders — including government, politicians, the media and patient advocate groups — to address the critical issues our members face and to push for progress. We educate policy makers about the needs of our members and advocate for legislation and policies essential to their growth and success.
Enabling Connections
Collaboration is key to moving bioscience forward. To support and enhance collaboration, the BIA brings together organisations from across the life sciences industry. This includes service providers, valued not only for the vital functions they serve in the sector, but also for their business acumen, expert guidance and industry connections.
The BIA hosts events throughout the year where members and others from the sector can learn, discuss, debate and network.
BIA Advisory Committee meetings connect peer groups to engage in debate and develop solutions to shared issues and challenges.
The BIA also keeps members connected and updated via regular communications. In addition, the BIA provides a host of other business development and business support services to enhance the value of membership. We facilitate introductions to other BIA members, provide meeting spaces at our central London office, offer member-only discounts to BIA and selected third-party events and also with suppliers.
In fulfilling its mission, the BIA aims to:
1 Offer a wide range of member services and benefits to the satisfaction of the membership
2 Represent the needs of the industry and its members on important issues
3 Promote best practice within the industry
4 Facilitate industry growth and maturity, positioning the UK as a leading world player in bioscience
5 Campaign for the best possible environment for innovative bioscience research
6 Communicate the benefits of innovative bioscience technologies
7 Maintain its role as the Association of choice for membership representation and communication on innovative bioscience issues
The BIA operates an active public affairs programme, a well-developed conference and and seminar programme, trade missions, regular publications for internal and external audiences, plus a series of committees whose interests range from regulatory affairs and intellectual property to personnel and finance and taxation. Networking and technology-transfer opportunities for members and others with an interest in the sector ensure that every avenue is explored in the support of UK bioscience.
Steve Bates, CEO of the UK BioIndustry Association (BIA) for over five years, shares the importance of the UK’s status as a global life science hub, the long-term government actions…
The UK has got around half of the public biotech companies and 21% of all entrepreneurial bioscience companies in Europe. From your perspective, can you explain what the key success…
Recently appointed as general manager & vice president of Gilead’s UK and Ireland operations, Hilary Hutton-Squire highlights the uniqueness of the UK’s healthcare system, its expertise in life sciences and…
Christine (Chris) Fox, VP and general manager UK and Ireland at Amgen, two months into her first country manager position and first time in a role outside of North America,…
Geoff Twist, managing director of Roche Diagnostics UK and Ireland, analyses the changing mindset he sees at various levels, leaning towards greater recognition of pathology’s impact on health systems. He…
Jeremy Thorpe established Tillotts Pharma’s operations in the UK, building his team around the central pillar of customer relationships. Jeremy explains how his company’s approach allowed it to reach £25…
Peter Burema, CEO of NextPharma, explains the specificities of a UK-based CDMO with manufacturing sites on the European continent. He describes how NextPharma refocused its efforts on being a customer-centric…
Laura McMullin, General Manager of the pharmaceutical division of Pierre Fabre in the UK and Ireland, explains the huge untapped potential of the organisation and her intention to make the…
With four out of the five NHS bodies, Leeds City Region is strongly anchored in the British life sciences ecosystem. Chair of Leeds City Region Enterprise Partnership, Roger Marsh OBE,…
Thembalath Ramachandran, chairman and managing director of one of the UK’s fastest growing generics manufacturers, Bristol Laboratories, describes why he chose to relocate from India to start his business, the…
Philip Lews Williams, managing director of the UK affiliate of French ophthalmology specialist Théa, describes the evolution of the company’s engagement in the UK and his strategy for taking on…
Having just announced a major investment into a new UK Discovery Centre in London that is set to open in 2020, MSD is committed to leverage on the UK’s potential…
Heading the Life Sciences strategy for Scotland’s main economic development agency Scottish Enterprise, Julia Brown recalls some of the region’s unique features making it an ideal place for life Sciences…
As all eyes are on Takeda these days after its announced acquisition of Shire, Jon Neal, managing director of the UK and Ireland operations of the Japanese player, looks back…
See our Cookie Privacy Policy Here